US Medicare Price Negotiation: Gaming FDA Approval Dates Could Delay Drug Selection
Executive Summary
The early February date for publishing the list of products eligible for price negotiations could dictate approval strategies for drugs with potential for big sales in Medicare going forward.
You may also be interested in...
UPDATED: US FDA Has People Working At CMS To Help Implement Inflation Reduction Act
The FDA was mum on the expertise that it appears to be lending the payer, but Commissioner Robert Califf reiterated that communication between the agency and CMS is increasing.
Medicare Drug Pricing Reform Is A Reality: Here Is What’s On The Agenda
Congressional Democrats achieved a long-sought goal in passing major legislation to control drug prices in Medicare. A complete lack of Republican support suggests the programs established by the bill will face the same kind of legislative and legal challenges that confronted the Affordable Care Act, which was enacted in a similar manner.
PBM Transparency Act Advances In Senate And It’s A Far Cry From The Rebate Rule
Bill aims to lower patient costs in part by engaging the US Federal Trade Commission to shed light on pharmacy benefit manager transactions with health plans, manufacturers and pharmacies.